Atlas FDA

DEFLUX INJECTABLE GEL

FDA premarket approval P000029/S012 · decided 2005-08-02

Approval details

PMA number
P000029
Supplement
S012
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
DEFLUX INJECTABLE GEL
Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Applicant
Palette Life Sciences
Date received
2005-04-08
Decision date
2005-08-02
Days to decision
116 days
Decision code
APPR
Product code
LNM
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Santa Barbara, CA
Statement
APPROVAL FOR MODIFICATION OF THE POST APPROVAL STUDY PROTOCOL TO: 1) REPLACE THE 1- AND 5-YEAR VOIDING CYSTOURETHROGRAM MEASUREMENTS WITH CLINICAL ASSESSMENTS OF "FEBRILE UTI;" AND 2) DECREASE THE TOTAL SAMPLE SIZE FROM 200 TO 149 PATIENTS.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Barrigel Injectable Gel (K220641)Palette Life Sciences2022-05-26